Sanofi upgraded by Morgan Stanley with a new price target
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley upgraded Sanofi from Equal-Weight to Overweight and set a new price target of $58.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2026 | Overweight → Equal-Weight | Morgan Stanley | |
| 4/20/2026 | $50.00 | Outperform → Neutral | BNP Paribas Exane |
| 2/12/2026 | Buy → Neutral | BofA Securities | |
| 1/27/2026 | Neutral | Citigroup | |
| 1/16/2026 | Buy → Neutral | UBS | |
| 1/6/2026 | Overweight → Equal Weight | Barclays | |
| 12/9/2025 | Buy → Neutral | Guggenheim | |
| 12/8/2025 | Overweight → Neutral | Analyst |
Submission status for CHATTEM SANOFI's drug XYZAL ALLERGY 24HR (SUPPL-10) with active ingredient LEVOCETIRIZINE DIHYDROCHLORIDE has changed to 'Approval' on 05/20/2026. Application Category: NDA, Application Number: 209089, Application Classification: Labeling
For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi
For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri
4 - Sanofi (0001121404) (Reporting)
3 - Sanofi (0001121404) (Reporting)
SD - Sanofi (0001121404) (Filer)
6-K - Sanofi (0001121404) (Filer)
13F-HR - Sanofi (0001121404) (Filer)
Morgan Stanley downgraded Sanofi from Overweight to Equal-Weight
BNP Paribas Exane downgraded Sanofi from Outperform to Neutral and set a new price target of $50.00
BofA Securities downgraded Sanofi from Buy to Neutral
Expansion to create 50 new high-skilled jobs in AI and reinforce Sanofi's long-term commitment to OntarioInvest Ontario Fund to contribute a conditional grant of up to $5 millionPartnership with the Province of Ontario and Toronto's strong AI talent pool key drivers in site selectionTORONTO, May 4, 2026 /CNW/ - Sanofi, an R&D-driven, AI-powered biopharma company and Canada's largest biopharma manufacturer, is expanding its global Artificial Intelligence (AI) Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture life-changing medicines and vaccines faster than ever before.
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe
Global HR leader to drive ITM's long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief People Officer (CPO). Ms. Breunig brings over 25 years of HR leadership experience at international pharmaceutical, manufacturing and technology companies, including at Siemens AG (FRA: SIE) and Sanofi (NASDAQ:SNY). At ITM, Ms. Breunig will lead the HR team in shaping strategies that unify the organization to achieve both team and business growth objectives while empowering em
Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for
Expansion to create 50 new high-skilled jobs in AI and reinforce Sanofi's long-term commitment to OntarioInvest Ontario Fund to contribute a conditional grant of up to $5 millionPartnership with the Province of Ontario and Toronto's strong AI talent pool key drivers in site selectionTORONTO, May 4, 2026 /CNW/ - Sanofi, an R&D-driven, AI-powered biopharma company and Canada's largest biopharma manufacturer, is expanding its global Artificial Intelligence (AI) Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture life-changing medicines and vaccines faster than ever before.
Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 seasonProvincial and territorial availability will be confirmed pending ongoing discussions and provincial assessmentsTransfer of market authorization from Novavax follows the strategic agreement signed between the two companies in May 2024This underscores Sanofi's commitment to public health and vaccine innovation in CanadaTORONTO, April 9, 2026 /CNW/ - Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe
SC 13G/A - Sanofi (0001121404) (Subject)
SC 13G - Sanofi (0001121404) (Filed by)
SC 13G/A - Sanofi (0001121404) (Subject)